Redox Balance in the Pathogenesis of Nonalcoholic Fatty Liver Disease: Mechanisms and Therapeutic Opportunities
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is currently the most common liver disease in the world. It encompasses a histological spectrum, ranging from simple, nonprogressive steatosis to nonalcoholic steatohepatitis (NASH), which may progress to cirrhosis and hepatocellular carcinoma. While liver-related complications are confined to NASH, emerging evidence suggests both simple steatosis and NASH predispose to type 2 diabetes and cardiovascular disease. The pathogenesis of NAFLD is currently unknown, but accumulating data suggest that oxidative stress and altered redox balance play a crucial role in the pathogenesis of steatosis, steatohepatitis, and fibrosis. We will examine intracellular mechanisms, including mitochondrial dysfunction and impaired oxidative free fatty acid metabolism, leading to reactive oxygen species generation; additionally, the potential pathogenetic role of extracellular sources of reactive oxygen species in NAFLD, including increased myeloperoxidase activity and oxidized low density lipoprotein accumulation, will be reviewed. We will discuss how these mechanisms converge to determine the whole pathophysiological spectrum of NAFLD, including hepatocyte triglyceride accumulation, hepatocyte apoptosis, hepatic inflammation, hepatic stellate cell activation, and fibrogenesis. Finally, available animal and human data on treatment opportunities with older and newer antioxidant will be presented. Antioxid. Redox Signal. 15, 1325–1365. I. Introduction: Importance of Nonalcoholic Fatty Liver Disease and of Altered Redox Balance for the APathogenesis of Nonalcoholic Fatty Liver Disease A. Summary II. Free Fatty Acid Oxidation as a Source of ROS A. Overview of hepatic fatty acid oxidative pathways and their altered homeostasis in NAFLD B. Mitochondrial FA oxidation: β-oxidation C. Peroxisomal β-oxidation D. Microsomal ω-oxidation of FAs: role of cytochrome P450 enzymes in the pathogenesis of NASH E. Summary III. Lysosomal-Mitochondrial Axis as a Mediator of FFA Hepatic Lipotoxicity in NASH A. Summary IV. Modulation of Mitochondrial Function and Potential Therapeutic Implications for NAFLD A. Inhibition of ACC system B. Modulation of PPAR-γ coactivator 1α gene activity C. Modulation of PPAR-α activity D. Modulation of PPAR-γ activity E. Modulation of PPAR-δ activity F. Summary V. Adipokines in NAFLD A. Leptin B. Tumor necrosis factor-α C. Resistin D. Adiponectin E. Retinol binding protein 4 F. Renin-angiotensin system G. Interleukin-6 H. Summary VI. Mechanisms of ROS-Induced Liver Injury in NAFLD A. Inhibition of very low-density lipoprotein secretion from hepatocytes B. JNK pathway activation C. TNF-α pathway activation D. ER stress in the pathogenesis of NASH E. Role of TG cellular stores in mitochondrial dysfunction and liver injury in NASH 1. ER stress and FFA overflow to the liver 2. ER stress and hepatic de novo lipogenesis 3. ER stress and hepatic VLDL secretion F. Role of free cholesterol in mitochondrial dysfunction and liver injury in NASH G. Summary VII. UCPs and Mitochondrial Dysfunction A. Summary VIII. Mitochondrial Dysfunction as a Link Between Maternal Fat Overnutrition and NASH in Adult Offspring A. Summary IX. Myeloperoxidase Involvement in Liver Injury in NASH A. Summary X. Nitrosative Stress in the Pathogenesis of NASH A. Summary XI. Oxidized LDL and Hepatic Fibrogenesis in NAFLD A. Summary XII. Antioxidant Systems in NAFLD A. Vitamin E B. Coenzyme Q10 (ubiquinone) C. Mitochondrial MnSOD D. Mitochondrial glutathione peroxidase E. Heme oxygenase F. Summary XIII. Newer Antioxidants with Potential Therapeutic Applications in NASH A. Silibinin/silymarin B. Curcumin C. Resveratrol D. Viusid E. Summary XIV. Concluding Remarks and Future Prospects
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Free Radicals in the Physiological Control of Cell Function
Dröge, W. (2002) · Physiological Reviews · doi:10.1152/physrev.00018.2001 · Cited by 9,855
Oxidants, antioxidants, and the degenerative diseases of aging.
Ames, B. N., Shigenaga, M. K., & Hagen, T. M. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.7915 · Cited by 5,958
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Obesity induces a phenotypic switch in adipose tissue macrophage polarization
Lumeng, C. N., Bodzin, J. L., & Saltiel, A. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29881 · Cited by 4,664 · cited 1×
“The presence of MPO in different macrophage populations may reflect a fine modulation of inflammatory status, which may alternatively promote or ameliorate obesity-associated chronic low-grade inflammatory status: M2 macrophages with tissue-remodeling and antiinflammatory capacities were depleted in obese adipose tiss…”
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238
Signal transduction by the JNK group of MAP kinases
Davis, R. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00116-1 · Cited by 4,237
Hayden, M. S., & Ghosh, S. (2004) · Genes & Development · doi:10.1101/gad.1228704 · Cited by 3,842
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Cited by
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941
Musso, G., Cassader, M., Rosina, F., & Gambino, R. (2012) · Diabetologia · doi:10.1007/s00125-011-2446-4 · Cited by 661
Self-citationMardinoglu, A., Wu, H., Bjornson, E., Zhang, C., Hakkarainen, A., Räsänen, S. M., Lee, S., Mancina, R. M., Bergentall, M., Pietiläinen, K. H., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.01.005 · Cited by 453
Oxidative Stress as a Critical Factor in Nonalcoholic Fatty Liver Disease Pathogenesis
Spahis, S., Delvin, E., Borys, J.-M., & Levy, E. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6776 · Cited by 386
Fructose metabolism in humans – what isotopic tracer studies tell us
Sun, S. Z., & Empie, M. W. (2012) · Nutrition & Metabolism · doi:10.1186/1743-7075-9-89 · Cited by 311
“However, all the factors linked to the development of fatty liver disease are not well understood and can include, insulin resistance, inflammation, fat redeposition, abnormalities in control of reactive oxygen species [21] and uncoupling proteins in mitochondria [22].”
Background
Metadata
- Authors
- Gambino, R., Musso, G., & Cassader, M.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2011-09
- Volume
- 15
- Issue
- 5
- Pages
- 1325-1365
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W2038028850
- Cited by
- 147
- References
- 75
- FWCI
- 6.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Redox Balance in the Pathogenesis of Nonalcoholic Fatty Liver Disease: Mechanisms and Therapeutic Opportunities. https://app.cochat.ai/papers/10.1089/ars.2009.3058
- The paper
- Gambino, R., Musso, G., & Cassader, M. (2011). Redox Balance in the Pathogenesis of Nonalcoholic Fatty Liver Disease: Mechanisms and Therapeutic Opportunities. Antioxidants & Redox Signaling. https://doi.org/10.1089/ars.2009.3058
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.